IL17A and neoplasm: Interleukin-17A is a pro-inflammatory cytokine that is associated with CRC progression, and regulates tumor cell growth and differentiation, as well as the tumor immune microenvironment.12 However, the predictive relevance of IL-17A in the clinical outcome and survival of CRC patients is ambiguous at present.29 Chen et al30 showed that high expression of IL-17A is a predictive marker of poor prognosis in CRC patients, whereas Tseng et al31 found that patients with higher serum levels of IL-17A had a shorter disease-free survival.